Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Peptide Hormone Analysis in Diagnosis and Treatment of Differences of Sex Development: Joint Position Paper of EU COST Action "DSDnet" and European Reference Network on Rare Endocrine Conditions

Research output: Contribution to journalJournal articlepeer-review

DOI

  1. Dynamic Changes in LH/FSH Ratios in Infants with Normal Sex Development

    Research output: Contribution to journalJournal articlepeer-review

  2. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Research output: Contribution to journalJournal articlepeer-review

  3. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Research output: Contribution to journalReviewpeer-review

  4. Increased liver fat associates with severe metabolic perturbations in low birth weight men

    Research output: Contribution to journalJournal articlepeer-review

  5. The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Research output: Contribution to journalJournal articlepeer-review

  1. Dynamic Changes in LH/FSH Ratios in Infants with Normal Sex Development

    Research output: Contribution to journalJournal articlepeer-review

  2. Oophorectomy and rate of dementia: a prospective cohort study

    Research output: Contribution to journalJournal articlepeer-review

  3. Pregnancy exposure to bisphenol A and duration of breastfeeding

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

Differences of Sex Development (DSD) comprise a variety of congenital conditions characterized by atypical chromosomal, gonadal, or anatomical sex. Diagnosis and monitoring of treatment of patients suspected of DSD conditions include clinical examination, measurement of peptide and steroid hormones, and genetic analysis. This position paper on peptide hormone analyses in the diagnosis and control of patients with DSD was jointly prepared by specialists in the field of DSD and/or peptide hormone analys is from the European Cooperation in Science and Technology (COST) Action DSDnet (BM1303) and the European Reference Network on rare Endocrine Conditions (Endo-ERN). The goal of this position paper on peptide hormone analysis was to establish laboratory guidelines that may contribute to improve optimal diagnosis and treatment control of DSD. The essential peptide hormones used in the management of patients with DSD conditions are follicle-stimulating hormone, luteinising hormone, anti-Müllerian hormone, and Inhibin B. In this context, the following position statements have been proposed: serum and plasma are the preferred matrices; the peptide hormones can all be measured by immunoassay, while use of LC-MS/MS technology has yet to be implemented in a diagnostic setting; sex- and age-related reference values are mandatory in the evaluation of these hormones; and except for Inhibin B, external quality assurance programs are widely available.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume182
Issue number6
Pages (from-to)P1-P15
ISSN0804-4643
DOIs
Publication statusPublished - Jun 2020

    Research areas

  • Anti-Mullerian Hormone/blood, Chromatography, Liquid/standards, Disease Management, Disorders of Sex Development/diagnosis, Europe, Female, Follicle Stimulating Hormone/blood, Humans, Immunoassay/standards, Inhibins/blood, Luteinizing Hormone/blood, Male, Peptide Hormones/blood, Practice Guidelines as Topic, Rare Diseases, Reference Standards, Tandem Mass Spectrometry/standards

ID: 59699090